ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2342

Redox Regulation of a New Autoimmune Mouse Model, Glucose-6-Phosphate Isomerase Peptide Induced Arthritis in Mice

Min Yang1 and Rikard Holmdahl2, 1Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, 2Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Redox Balance and animal models, ROS

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose

Rheumatoid arthritis (RA) is a perpetuating disease, which affects approximately 1% of the population. Until now, the pathogenic mechanisms of RA remain elusive and currently no cure for the disease. Animal models of arthritis have provided valuable platforms to investigate the potential mechanisms of RA and test new therapeutic principles before initiating clinical trials in humans. Based on the well-known K/BxN model, a spontaneous arthritis mouse model, we have established glucose-6-phosphate isomerase (G6PI) peptide induced arthritis in mice. Since the G6PI peptide used in this model has two cysteines inside, therefore, we focus on how redox balance could affect antigen recognition and thereby affect the pathogenesis of autoimmunity.

Methods

G6PI peptide-induced arthritis is established by immunizing C57Bl/6N.Q (B6N.Q) mice or Ncf1*/* mice with single injection of G6PI peptide emulsified in complete freund’s adjuvant. Cysteine(s) in the peptide is substituted with serine to test whether redox can influence peptide itself.  APCs from both wild type and Ncf1*/* mice are isolated, loaded with G6PI peptide or substituted peptide and cocultured with peptide-specific T cell hybridoma for 24hr. Supernatants are collected then to compare the IL-2 secretion level.

Results

Immunized B6N.Q mice start to develop arthritis on day 10-12, reach to the peak value of severity on day 14-20 and then recover during following 7-10 days. Moreover, both female and male B6N.Q mice could be induced arthritic diseases by G6PI peptide and the incidence is over 80%. Obviously, this peptide-induced arthritis mouse model represents an acute arthritic disease progression. To establish a chronic mouse model with this peptide, we inject pertussis toxin together with G6PI emulsion. It turns out that pertussis toxin not only increases the severity of the disease but also prolong the disease progression over two months. To investigate whether cysteine inside of the peptide is regulated by redox, Ncf1 mutant mice were used. Ncf1 encodes p47phox subunit, which is an essential cytosolic subunit of NADPH oxidase 2 (Nox2). The mutation of Ncf1 results in the deficiency of ROS production. The in vitro assay suggest that APCs from Ncf1*/* mice show higher capability to present G6PI peptide. However, when either one or both of the cysteine substituted with serine, there is no difference at all in antigen presenting between wild type and Ncf1*/* mice. Furthermore, peptide immunized Ncf1*/* mice exhibit more severe and chronic disease comparing with immunized wild type mice. 

Conclusion

Taken together, we have established a peptide-induced arthritis mouse model. The model is induced with a defined peptide, leading to a high reproducibility and allowing a more precise investigation of the pathogenicity. Since the peptide per se is sensitive to ROS level, therefore, this model provides unique possibility to investigate redox regulation in autoimmune disease including RA.

 


Disclosure:

M. Yang,
None;

R. Holmdahl,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/redox-regulation-of-a-new-autoimmune-mouse-model-glucose-6-phosphate-isomerase-peptide-induced-arthritis-in-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology